Oral ketamine is antinociceptive in the rat formalin test: Role of the metabolite, norketamine

Pain

Volumn 81, Issue 1-2, 1999, Pages 85-93

  Shimoyama, Megumi ^a,b   Shimoyama, Naohito ^a,b   Gorman, A Laurel ^a,b   Elliott, Kathryn J ^a,b   Inturrisi, Charles E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Dept Neurol Mem Sloan K   (United States)

Author keywords

Antinociception; Formalin; Ketamine; N methyl D aspartate receptor; Norketamine; Oral administration

Indexed keywords

DIZOCILPINE; DRUG METABOLITE; FORMALDEHYDE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG RECEPTOR BINDING; INTRATHECAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CENTRAL NERVOUS SYSTEM; FORMALDEHYDE; INJECTIONS, SPINAL; KETAMINE; MALE; NOCICEPTORS; OSMOLAR CONCENTRATION; PAIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032947439     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(98)00269-3     Document Type: Article

References (58)

1. Alderson P.J., Lerman J. Oral premedication for paediatric ambulatory anaesthesia: a comparison of midazolam and ketamine. Can. J. Anaesth. 41:1994;221-226.
2. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-D-aspartate. Br. J. Pharmacol. 79:1983;565-575.
3. Arendt-Nielsen L., Petersen-Felix S., Fischer M., Bak P., Bjerring P., Zbinden A.M. The effect of N-Methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study. Anesth. Analg. 81:1995;63-68.
4. Backonja M., Arndt G., Gombar K.A., Check B., Zimmerman M. Response of chronic neuropathic pain syndrome to ketamine: a preliminary study. Pain. 56:1994;51-57.
5. Baumeister A., Advokat C. Evidence for a supraspinal mechanism in the opioid-mediated antinociceptive effect of ketamine. Brain Res. 566:1991;351-353.
6. Bovill J.G., Dundee J.W. Alterations in response to somatic pain associated with anaethesia XX: ketamine. Br. J. Anaesth. 43:1971;496-499.
7. Bragg C.L., Miller B.R. Oral ketamine facilitates induction in a combative mentally retarded patient. J. Clin. Anesth. 2:1990;121-122.
8. Broadley K.E., Kurowska A., Tookman A. Ketamine injection used orally. Palliat. Med. 10:1996;247-250.
9. Chaplan S.R., Malmberg A.B., Yaksh T.L. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J. Pharmacol. Exp. Ther. 280:1997;829-838.
10. Clark J.L., Kalan G.K. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J. Pain Symptom Manage. 10:1995;310-314.
11. Clements J.A., Nimmo W.S., Grant I.S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J. Pharmacol. Sci. 71:1982;539-542.
12. Coderre T.J., Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J. Neurosci. 12:1992;3665-3670.
13. Coderre T.J., Katz J., Vaccarino A.L., Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 52:1993;259-285.
14. Cohen M.L., Chan S.-L., Way W.L., Trevor A.J. Distribution in the brain and metabolism of ketamine in the rat after intravenous administration. Anesthesiology. 39:1973;370-376.
15. Cohen M.L., Trevor A.J. On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J. Pharmacol. Exp. Ther. 189:1974;351-358.
16. Crisp T., Perrotti J.M., Smith D.L., Stafinsky J.L., Smith D.J. The local monoaminergic dependency of spinal ketamine. Eur. J. Pharmacol. 194:1991;167-172.
17. Dickenson, A.H. and Sullivan, A.F., Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation, Neuropharmacology, 26 (1987a) 1235-1238.
18. Dickenson, A.H. and Sullivan, A.F., Subcutaneous formalin-induced activity of dorsal horn neurons in the rat: differential response to an intrathecal opiate administration pre or post formalin, Pain, 30 (1987b) 349-360.
19. Dubner R., Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15:1992;96-103.
20. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 4:1977;161-174.
21. Ebert B., Mikkelsen S., Thorkildsen C., Borgbjerg F.M. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur. J. Pharmacol. 333:1997;99-104.
22. Eide P.K., Jørum E., Stubhaug A., Bremnes J., Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain. 58:1994;347-354.
23. Elliott K.J., Brodsky M., Hynansky A.D., Foley K.M., Inturrisi C.E. Dextromethorphan suppresses both formalin-induced nociceptive behavior and the formalin-induced increase in spinal cord c-fos mRNA. Pain. 61:1995;401-409.
24. Finck A.D., Samaniego E., Ngai S.H. Morphine tolerance decreases the analgesic effects of ketamine in mice. Anesthesiology. 68:1988;397-400.
25. France C.P., Snyder A.M., Woods J.H. Analgesic effects of phencyclidine-like drugs in Rhesus monkeys. J. Pharmacol. Exp. Ther. 250:1989;197-201.
26. Gorman A.L., Elliott K.J., Inturrisi C.E. The D- and L-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. 223:1997;5-8.
27. Grant I.S., Nimmo W.S., Clements J.A. Pharmacokinetics and analgesic effects of intramuscular and oral ketamine. Br. J. Anaesth. 53:1981;805-810.
28. Gutstein H.B., Johnson K.L., Heard M.B., Gregory G.A. Oral Ketamine preanesthetic medication in children. Anesthesiology. 76:1992;28-33.
29. Haley J.E., Sullivan A.F., Dickenson A.H. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Res. 518:1990;218-226.
30. Hoffmann V., Coopejans H., Vercauteren M., Adriaensen H. Successful treatment of postherpetic neuralgia with oral ketamine. Clin. J. Pain. 10:1994;240-242.
31. Inturrisi C.E., Colburn W.A., Verebey K., Dayton H.E., Woody G.E., O'Brien C.P. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyhene. Clin Pharmacol. Ther. 31:1982;157-167.
32. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of noncompetitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry. 51:1994;199-214.
33. Leung L.Y., Baillie T.A. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J. Med. Chem. 29:1986;2396-2399.
34. MacDonald J.F., Miljkovic Z., Pennefather P. Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J. Neurophysiol. 58:1987;251-266.
35. Mao J., Price D.D., Hayes R.L., Lu J., Mayer D.J., Frenk H. Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy. Brain Res. 605:1993;164-168.
36. Martin D., Lodge D. Ketamine acts as a non-competitive N-Methyl-D-aspartate antagonist on frog spinal cord in vitro. Neuropharmacology. 24:1985;999-1003.
37. Maurset A., Skoglund L.A., Hustveit O., Øye I. Comparison of ketamine and pethidine in experimental and postoperative pain. Pain. 36:1989;37-41.
38. Max M.B., Byas-Smith M.G., Gracely R.H., Bennett G.J. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin. Neuropharmacol. 18:1995;360-368.
39. McCall W.D., Tanner K.D., Levine J.D. Formalin induces biphasic activity in C-fibers in the rat. Neurosci. Lett. 208:1996;45-48.
40. Oshima E., Tei K., Kayazawa H., Urabe N. Continuous subcutaneous injection of ketamine for cancer pain. Can. J. Anaesth. 37:1990;385-386.
41. Petros A.J. Oral Ketamine: its use for mentally retarded adults requiring day are dental treatment. Anaesthesia. 46:1991;646-647.
42. Qureshi F.A., Mellis P.T., MaFadden M.A. Efficacy of oral ketamine for providing sedation and analgesia to children requiring laceration repair. Pediatr. Emerg. Care. 11:1995;93-97.
43. Ren K., Williams G.M., Hylden J.L.K., Ruda M.A., Dubner R. The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuate carrageenan-induced behavioral hyperalgesia in rats. Eur. J. Pharmacol. 219:1992;235-243.
44. Ryder S., Way W.L., Trevor A.J. Comparative pharmacology of the optical isomers of ketamine in mice. Eur. J. Pharmacol. 49:1978;15-23.
45. Sadove M.S., Shulman M., Hatano S., Fevold N. Analgesic effect of ketamine administered in subdissociative doses. Anesth. Analg. 50:1971;452-457.
46. Shimoyama, M., Shimoyama, N., Inturrisi, C.E. and Elliott, K., Oral ketamine produces dose-dependent CNS depression in the rat, Life Sci., 60 (1996a) PL9-14.
47. Shimoyama, N., Shimoyama, M., Inturrisi, C.E. and Elliott, K.J., Ketamine attenuates and reverses morphine tolerance in rodents, Anesthesiology, 85 (1996b) 1357-1366.
48. Skilling S.R., Smullin D.H., Larson A.A. Extracellular amino acid concentrations in the dorsal spinal cord of freely moving rats following veratridine and nociceptive stimulation. J. Neurochem. 51:1988;127-132.
49. Slogoff S., Allen G.W., Wessels J.V., Cheney D.H. Clinical experience with subanesthetic ketamine. Anesth. Analg. 53:1974;354-358.
50. Stannard C.F., Porter G.E. Ketamine hydrochloride in the treatment of phantom limb pain. Pain. 54:1993;227-230.
51. Tobias J.D., Phipps S., Smith B., Mulhern R.K. Oral ketamine premedication to alleviate the distress of invasive procedures in pediatric oncology patients. Pediatrics. 90:1992;537-541.
52. Tung A.S., Yaksh T.L. Analgesic effect of intrathecal ketamine in the rat. Regul. Anesth. 6:1981;91-94.
53. Vaccarino A.L., Marek P., Kest B., Weber E., Keana J.F., Liebeskind J.C. NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res. 615:1993;331-334.
54. White P.F., Johnston R.R., Pudwill C.R. Interaction of ketamine and halothane in rats. Anesthesiology. 42:1975;179-186.
55. Woolf T.F., Adams J.D. Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations. Xenobiotica. 17:1987;839-847.
56. Woolf C.J., Thompson S.W.N. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain. 44:1991;293-299.
57. Yamamoto, T. and Yaksh, T.L., Comparison of the antinociceptive effects of pre- and posttreatment with intrathecal morphine and MK801, an NMDA antagonist, on the formalin test in the rat, Anesthesiology, 77 (1992a) 757-763.
58. Yamamoto, T. and Yaksh, T.L., Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists, Pain, 49 (1992b) 121-128.